EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Therapeutic targeting of microtubule affinity‐regulating kinase 4 in cancer and neurodegenerative diseases

Manzar Alam, Sarfraz Ahmed, Mohammad Abid, Gulam Mustafa Hasan, Asimul Islam iD, Md Imtaiyaz Hassan iD

Journal of Cellular Biochemistry · 2023-09 · 124 (9) · 1223-1240

DOI: 10.1002/jcb.30468 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Cellular Biochemistry, online erschienen am 03.09.2023. Verfasst von Manzar Alam und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, India. Hauptthemen laut MEDLINE: Neurodegenerative Diseases, Alzheimer Disease, Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 154 Literaturangaben. Gefördert von: Indian Council of Medical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Microtubule affinity‐regulating kinase 4 (MARK4) is a member of the Ser/Thr protein kinase family, phosphorylates the microtubule‐connected proteins and plays a vital role in causing cancers and neurodegenerative diseases. This kinase modulates multiple signaling pathways, including mammalian target of rapamycin, nuclear factor‐κB, and Hippo‐signaling, presumably responsible for cancer and Alzheimer's. MARK4 acts as a negative controller of the Hippo‐kinase cassette for promoting YAP/TAZ action, and the loss of MARK4 detains the tumorigenic properties of cancer cells. MARK4 is involved in tau hyperphosphorylation that consequently affects neurodegeneration. MARK4 is a promising drug target for cancer, diabetes, and Alzheimer's. Developing the potent and selective inhibitors of MAKR4 are promising in the therapeutic management of associated diseases. Despite its great significance, a few reviews are available to discuss its structure, function and clinical significance. In the current review, we aimed to provide detailed information on the structural features of MARK4 targeted in drug development and its role in various signaling pathways related to cancer and neurodegenerative diseases. We further described the therapeutic potential of MARK4 inhibitors in preventing numerous diseases. Finally, the updated information on MARK4 will be helpful in the further development of effective therapeutic molecules.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neurodegenerative DiseasesAlzheimer DiseaseNeoplasmsHumansCarcinogenesisMicrotubule ProteinsMicrotubules

Stichwörter der Autor:innen

NF-κBcancerkinase inhibitorsmTOR signalingmicrotubule affinity-regulating kinase 4target therapy

Substanzen

Microtubule Proteins

Autor:innen und Institutionen

  • Center for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, India.
  • Department of Biosciences, Jamia Millia Islamia, New Delhi, India.
  • Department of Biochemistry, College of Medicine, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia.

ORCID-Profile: Asimul Islam, Md Imtaiyaz Hassan

Förderung

  • Indian Council of Medical Research

Zitieren

APA

Alam, M., Ahmed, S., Abid, M., Hasan, G. M., Islam, A., & Hassan, M. I. (2023). Therapeutic targeting of microtubule affinity‐regulating kinase 4 in cancer and neurodegenerative diseases. Journal of Cellular Biochemistry, 124(9), 1223-1240. https://doi.org/10.1002/jcb.30468

Vancouver

Alam M, Ahmed S, Abid M, Hasan GM, Islam A, Hassan MI. Therapeutic targeting of microtubule affinity‐regulating kinase 4 in cancer and neurodegenerative diseases. Journal of Cellular Biochemistry. 2023;124(9):1223-1240. doi:10.1002/jcb.30468

BibTeX
@article{Alam2023,
  author = {Alam, Manzar and Ahmed, Sarfraz and Abid, Mohammad and Hasan, Gulam Mustafa and Islam, Asimul and Hassan, Md Imtaiyaz},
  title = {Therapeutic targeting of microtubule affinity‐regulating kinase 4 in cancer and neurodegenerative diseases},
  journal = {Journal of Cellular Biochemistry},
  year = {2023},
  volume = {124},
  number = {9},
  pages = {1223--1240},
  doi = {10.1002/jcb.30468}
}
Kostenlos starten →